Drug Profile
Trimetazidine - Saghmos Therapeutics
Alternative Names: ST-62516Latest Information Update: 15 Mar 2024
Price :
$50
*
At a glance
- Originator Saghmos Therapeutics
- Class Anti-ischaemics; Cytoprotectives; Hepatoprotectants; Ischaemic heart disorder therapies; Piperazines; Small molecules; Vasodilators
- Mechanism of Action Adenosine triphosphatase inhibitors; Calcium channel antagonists; Free radical scavengers; Platelet aggregation inhibitors; Thromboxane synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Acute kidney injury
Most Recent Events
- 13 Mar 2024 Saghmos Therapeutics received a Notice of Allowance from the Japanese Patent Office for a patent for ST-62516 (trimetazidine)
- 07 Feb 2024 Saghmos Therapeutics has patent protection for trimetazidine in USA
- 04 Oct 2023 Preclinical development is still ongoing in Acute kidney injury in USA